Navigation Links
MetaStat, Inc. Announces Allowance of Patent Claims
Date:7/10/2012

THE WOODLANDS, Texas, July 10, 2012 /PRNewswire/ -- MetaStat, Inc. (OTCBB: MTST) announced today that it has received notice of allowance from the U.S. Patent Office for U.S. Patent Application No. 11/659,514 and notice of allowance of European Patent Application no. 05807467.5. The patent applications are entitled: Isolation, Gene Expression, and Chemotherapeutic Resistance of Motile Cancer Cells, Inventor:  John S. Condeelis, Professor and Co-Chair, Anatomy & Structural Biology, the Judith and Burton P. Resnick Chair in Translational Research, and Co-Director, Gruss Lipper Biophotonics Center, Albert Einstein College of Medicine of Yeshiva University. The technology covered by the allowed claims includes methods for the recovery of pure populations of highly metastatic cells, their gene expression profile, and materials and methods for the evaluation of their response to chemotherapy.

"Isolation, Gene Expression, and Chemotherapeutic Resistance of Motile Cancer Cells" describes an "artificial blood vessel" that was developed to mimic the chemical attraction exerted on highly metastatic cells by the tumor vasculature. This is the first method available to actually isolate, collect, genetically profile, and determine chemotherapeutic resistance of a pure population of metastatic cancer cells from a tumor. Previously, attempts to genetically profile these dangerous cells were thwarted because tumor samples available for analysis contained large proportions of proliferative and structural cells and only a tiny proportion of metastatic cells.

About MetaStat, Inc.

MetaStat is a life science company focused on the development and commercialization of proprietary clinical diagnostic tests that predict the probability of systemic hematogenous (blood borne) metastasis of cancer, as well as companion therapeutics to prevent this deadly spread. We believe our initial product, the MetaSite Breast™ test, will predict the probability that cancer will be disseminated by this means to other organs in the body. MetaSite Breast could be a breakthrough for breast cancer patients and their doctors because metastasis is responsible for almost 90% of fatalities from breast cancer.  Further, the platform technology underlying this diagnostic approach may be applicable in up to 80% of all solid tumor cancers, including prostate, lung, colorectal, head and neck, and pancreatic.  Most significantly, we believe our platform technology provides us with targets of intervention in key pathways for the development of the first therapies that may preemptively reduce or eliminate metastasis thereby dramatically reducing fatalities.

Our technology platform and corresponding products result from over 15 years of collaboration involving four scientific institutions. We believe we are unique and differentiated in the marketplace because our discoveries are based on direct microscopic visualization of living, functioning tumors in vivo. We have observed the behavior of metastatic cells as they migrate to and penetrate blood vessels, where they are subsequently carried away to establish distant site metastases.

For More Information, Contact: Warren C. Lau President & CEO MetaStat, Inc. (281) 363-0003


'/>"/>
SOURCE MetaStat, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
3. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
4. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
5. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
6. WuXi PharmaTech Announces Third-Quarter 2011 Results
7. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
8. Spherix Announces Third Quarter Financial Results
9. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
10. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
11. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... ... Lithography Equipment for the Semiconductor, MEMS, and Microfluidics Industries, announces the new Model ... specifications found more often in automated production mask aligners. OAI has already received ...
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... ... changing into a different cell type. Many treatments for specific cancers, such as ... example of targeted treatment is androgen deprivation therapy for advanced prostate cancer. ...
(Date:8/16/2017)... OXFORD, England , Aug. 16, 2017  Kingfisher Talent, ... search and leadership development, and Virdis Group, global executive search ... exclusive alliance that enables clients to leverage the expertise and ... "For our clients here in the Boston ... diverse population of leadership talent throughout the US, ...
(Date:8/15/2017)... (PRWEB) , ... August 15, 2017 , ... Any expert ... that has compromised these disciplines for more than half a century. Despite their ... counted. It is widely known that molecular tags developed for this purpose also ...
Breaking Biology Technology:
(Date:5/23/2017)... 2017  Hunova, the first robotic gym for the rehabilitation and functional ... in Genoa, Italy . The first 30 robots will ... USA . The technology was developed and patented at ... IIT spin-off Movendo Technology thanks to a 10 million euro investment from ... click: ...
(Date:5/6/2017)... SINGAPORE , May 5, 2017 ... has just announced a new breakthrough in biometric ... that exploits quantum mechanical properties to perform ... new smart semiconductor material created by Ram Group ... across finance, entertainment, transportation, supply chains and security. ...
(Date:4/18/2017)... , April 18, 2017  Socionext Inc., a global expert in ... media edge server, the M820, which features the company,s hybrid codec ... provided by Tera Probe, Inc., will be showcased during the upcoming ... NAB show at the Las Vegas Convention ... Click ...
Breaking Biology News(10 mins):